The INVEST Precision Medicine Conference June 9-11Held online, it will explore a wide range of topics from developing advanced treatments for rare diseases and cancer, genetic testing, health equity, pediatric innovation, and more.
To view the full agenda, click here. To register for free, click here.
But like all MedCity events, startups will also be in the spotlight. The Startup Pitch Perfect Presentation Contest includes the Health IT track, scheduled for June 9 from 3:30-5pm ET and the Life Science track scheduled for June 10 from 3:30pm-5pm ET. Earlier this week, we reviewed life sciences pathway companies. Here is a look at companies in the health IT path:
BioXplor Developed a proprietary biomedical data platform and product suite of tools and algorithms for clinical responder analysis, drug combinations, and indication scaling.
Intellihealth It is a medical technology company that is transforming the concept and treatment of obesity. Building on 30 years of clinical experience, our data-driven technology allows us to tackle the obesity epidemic at scale by providing any medical provider with a comprehensive, turnkey solution to treat obese patients either remotely or in person. Our program integrates with electronic health records to improve outcomes and increase cost savings by customizing and improving the diagnosis, prescribing process, and comprehensive treatment plan for treating obesity as a disease. Providers benefit from new revenue through more effective patient interactions and improved billing, while taxpayers and self-insured organizations achieve significant health-related cost savings through a healthier workforce.
Vocalis Health is an AI-powered health technology company pioneering the development of acoustic biomarkers – where health-related information is derived from analysis of people’s audio recordings – to screen, detect, monitor, and predict health symptoms, conditions and diseases. Vocalis Health is currently focusing on screening users for Covid-19 and monitoring patients with chronic conditions such as chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF) and pulmonary hypertension.
phenobium On a mission to become the gold standard for developing microbiome-based solutions, from assay development to therapeutics, across human, animal and agricultural technology markets.
AIQ Solutions Developed a revolutionary software technology that will change the way clinicians manage complex diseases such as metastatic cancer and neurological disorders. The cloud platform provides unique early-stage intelligence to predict both treatment efficacy and toxicity risk from longitudinal imaging data. AIQ does not diagnose disease; Rather, it enables the clinical team to make real-time, patient-specific adjustments to treatment, helping to improve outcomes while reducing costs to the healthcare system. AIQ has built and validated its product, received FDA clearance, and is on track to recognize $1 million in revenue in 2021. The company is actively seeking $10 million in Series A-1 support for marketing activities.
picture: Adam Taylor, Getty Images